EMX2OS and nonpapillary renal cell carcinoma: Then, according to the results of drug susceptibility test (Figure 7E,F,K,L), we found that sensitivity to 6 drugs (A‐83‐01, SB52334, SB505124, Ibrutinib, Sinularin, OF‐1) for ccRCC was negatively associated with expression of EMX2OS.